• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NewGen to Execute Up to US$2 Million Share Repurchase Program Through Benchmark

    1/27/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care
    Get the next $NIVF alert in real time by email

    BANGKOK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that it intends to execute its previously authorized share repurchase program initially announced on November 10, 2025 through The Benchmark Company, LLC ("Benchmark"), a subsidiary of StoneX Group Inc. ("StoneX").

    Management believes that NewGen's current market valuation does not fully reflect the Company's underlying business fundamentals, ongoing initiatives, and long-term strategic potential. The use of Benchmark represents a key step in the disciplined implementation of the Company's capital allocation strategy and underscores management's confidence in NewGen's future trajectory.

    As previously announced, NewGen's Board of Directors authorized a share repurchase program of up to US$2 million, to be executed in the open market in accordance with applicable securities laws and regulations. The Company expects to utilize Benchmark's institutional trading platform and execution capabilities based on its robust institutional trading capabilities, compliance framework, and experience in liquidity-sensitive execution for Nasdaq-listed issuers.

    Benchmark will handle the execution and operational aspects of trades under the program in accordance with applicable regulatory requirements.

    Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, commented, "We continue to believe that the market does not fully recognize the value of our business, the progress we have made, or the scale of opportunities ahead of us. Working with Benchmark as our executing broker allows us to implement our share repurchase program with discipline and transparency. This program reflects our confidence in NewGen's long-term fundamentals and our commitment to allocating capital in a way that supports shareholder value, and we consider it a core part of our development strategy."

    The share repurchase program allows the Company to repurchase its shares from time to time through open market purchases or other permitted methods, subject to market conditions, share price, trading volume, and other relevant factors. The program does not obligate the Company to repurchase any specific number of shares and may be modified, suspended, or terminated at any time.

    The statements in this press release regarding the Company's market valuation and intrinsic value reflect management's current views and assumptions based on available information. These views are subjective, may not be accurate, and should not be relied upon as investment advice. Investors should conduct their own analysis and consult with financial advisors. The Company's assessment of value is not based on any fairness opinion, independent valuation, or third-party analysis.

    About NewGen

    NewGenIVF Group is a tech-forward, diversified, multi-jurisdictional entity capitalizing on emerging opportunities across real estate development, digital asset innovation and reproductive health solutions. The Company operates through three strategic business divisions that leverage cutting-edge technology and innovative solutions to drive sustainable growth and high ROI for shareholders across multiple global markets. These include "NewGenProperty", which operates real estate development projects in the UAE's Ras Al Khaimah Emirate; "NewGenDigital", which serves as the Company's digital asset and DeFi solutions arm; and "NewGenSup", which focuses on health and longevity products and solutions. NewGen's legacy business involves providing industry-leading IVF and assisted reproductive treatment services across Asia. With operations spanning multiple jurisdictions and a commitment to innovative, technology-enabled solutions, NewGenIVF Group is uniquely positioned to capitalize on the convergence of real estate, healthcare and digital asset opportunities in the evolving global economy.

    To learn more, visit www.newgenivf.com. The information contained on, or accessible through, NewGen's website is not incorporated by reference into this press release, and you should not consider it a part of this press release.

    Forward-Looking Statements

    This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar statements. Without limiting the generality of the foregoing, forward-looking statements in this press release include but are not limited to: statements regarding management's beliefs about the Company's intrinsic value and market valuation; statements about the Company's business fundamentals, growth initiatives, and long-term strategic potential; statements about the Company's future trajectory and opportunities; statements regarding the implementation and execution of the share repurchase program, including the timing, amount, method, and impact of any repurchases; statements about the Company's capital allocation strategy and its effect on shareholder value; statements characterizing the Company as a "high-growth entity"; statements about the Company's ability to capitalize on opportunities in real estate development, digital asset management, and reproductive health solutions; statements describing real estate projects as promising "high ROI"; statements about the Company's digital asset and DeFi operations and their potential; statements about driving sustainable growth; and statements about the Company's positioning in global markets.

    Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. A number of factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the following: the Company's ability to successfully implement and complete the share repurchase program, which may be modified, suspended, or terminated at any time and is subject to market conditions, available liquidity, compliance with applicable laws and regulations, and the Company's financial condition; the Company's assessment of its intrinsic value may not be accurate and the market may never reflect management's valuation views; the Company's liquidity position and capital resources may be insufficient to fund the repurchase program while simultaneously meeting operational needs, debt obligations, and other commitments; the share repurchase program may not enhance shareholder value and could reduce the Company's financial flexibility; trading volume, market volatility, and other market conditions may prevent or limit the Company's ability to execute repurchases at favorable prices or at all; the Company's financial condition, results of operations, cash flows, and business prospects may deteriorate from current expectations, which could impact the Company's ability to execute the repurchase program or could make the valuation assumptions underlying management's statements inaccurate; the characterization of the Company's businesses as "high-growth," or positioned for "high ROI" reflects management's current views and assumptions, which may not materialize and actual results may differ materially; and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    All information provided in this press release is as of the date of this press release, and NIVF does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    Investor Relations Contact

    ICR, LLC

    Robin Yang

    Phone: +1 (212) 537-3847

    Email: [email protected]



    Get the next $NIVF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NIVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NIVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chardan Capital Markets Llc claimed ownership of 1,569,000 units of Class A Ordinary Shares (SEC Form 3)

    3 - NewGenIvf Group Ltd (0001981662) (Issuer)

    11/13/24 9:16:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    SEC Filings

    View All

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    1/20/26 8:07:33 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    12/2/25 8:01:34 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    11/25/25 4:00:29 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewGen and Evident Capital Successfully Activate Commitment Campaign for Inaugural Tokenized Real Estate Bond, Delivering on Cross-Border Real World Asset Financing Strategy

    Rapid progress from announcement of successful launch in under two weeks signals NewGen's expertise and commitment Launch represents fulfilment of NewGen's goals to spearhead Real World Asset tokenization, puts Company at the forefront of digital assets innovation BANGKOK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, is pleased to announce that the Commitment Campaign for its inaugural tokenized bond issuance is now live on Evident Ca

    2/4/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen to Execute Up to US$2 Million Share Repurchase Program Through Benchmark

    BANGKOK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that it intends to execute its previously authorized share repurchase program initially announced on November 10, 2025 through The Benchmark Company, LLC ("Benchmark"), a subsidiary of StoneX Group Inc. ("StoneX"). Management believes that NewGen's current market valuation does not fully reflect the Company's underlying business fundamentals, ongoing initiatives, and

    1/27/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts

    BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (("NewGen" or the "Company, NASDAQ:NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced the appointment of award-winning Web3 legal and regulatory specialist Joshua Chu as Senior Counsel to lead the Group's tokenization strategy, alongside the formal engagement of Evident Capital, Hong Kong's first fully integrated, SFC-licensed tokenization and alternative assets platform, to support the launch of NIVF's inaugural tokenized bond issuance of up to USD 30 million targeted for completion by the first quarter of 2026. As S

    1/21/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Leadership Updates

    Live Leadership Updates

    View All

    NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts

    BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (("NewGen" or the "Company, NASDAQ:NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced the appointment of award-winning Web3 legal and regulatory specialist Joshua Chu as Senior Counsel to lead the Group's tokenization strategy, alongside the formal engagement of Evident Capital, Hong Kong's first fully integrated, SFC-licensed tokenization and alternative assets platform, to support the launch of NIVF's inaugural tokenized bond issuance of up to USD 30 million targeted for completion by the first quarter of 2026. As S

    1/21/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGenDigital Appointed as SAXA Inc.'s Agent for Tokenization of US$100 Million of Gold-backed Assets

    Service agreement with SAXA, Inc. appoints NewGenDigital as SAXA's worldwide tokenization agent, strengthening cooperation between the two companies ahead of proposed reverse merger Value of tokenized assets could be expanded to US$1 billion under the terms of the agreement; NewGenDigital to earn 5% commission on assets sold BANGKOK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that its subsidiary, NewGenD

    11/5/25 9:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

    Company Granted Request to Continue its Listing on NasdaqAppoints Thorain Ko to Lead Business Development Initiatives BANGKOK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to specific conditions. Additionally, the Company announced the appointment of Mr. Thorain Ko as Business Development Director to drive its expansion initiatives. Nasdaq Listing UpdateThe Pane

    2/20/25 6:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    11/13/24 9:19:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    10/10/24 3:39:26 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care